Feasibility Study for Repurposing RET Inhibitors

Inclusion Criteria: * Histologically confirmed and documented locally advanced or metastatic NSCLC, pancreatic ductal adenocarcinoma, or colorectal cancer * Patient is currently receiving platinum-based therapy for cancer treatment * Patients on stable EPI * Written informed consent signed and dated by the patient prior to the performance of any study-specific procedures, sampling, or analyses * At least 18 years-of-age at the time of signature of the informed consent form (ICF) * Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0, 1, or 2 * Plasma GDF-15 level is at least 1500pg/mL * Life expectancy exceeds 4 months, as judged by investigator * Cachexia, defined as weight loss of \>5% body weight in the past 6 months, OR weight loss of \>2% body weight in the past 6 months with BMI \< 20 Exclusion Criteria: * ECOG Performance Score of 3 or 4 * Is pregnant or plans to become pregnant during study duration (if patient is of childbearing potential) or plans to make someone pregnant during study duration. * Patient has not experienced significant weight loss (defined as loss of \>5% body weight in the past 6 months, OR loss of \>2% body weight in the past 6 months with BMI \< 20)† * Out-of-range laboratory values defined as: * Absolute neutrophil count (ANC) \<1.5 x 109/L * Hemoglobin (Hgb)90 g/L or \<9 g/dL * Platelets \<100 x 109/L * Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) \>2.5 x the upper limit of normal (ULN) if n…